AARP Hearing Center
The Trump administration Wednesday outlined a framework for allowing prescription drugs to be imported from Canada and other foreign countries, something that could help consumers better afford the medicines they need to stay healthy.
The Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) released a two-pronged approach to importing cheaper drugs from abroad. The Safe Importation Action Plan does not include a specific timetable.
“This is the next important step in the Administration's work to end foreign freeloading and put American patients first,” HHS Secretary Alex Azar said in a statement. Azar has historically opposed allowing medications to be brought in from other countries, but this year the president directed him to work with Florida and other states on their plans for drug importation. A provision in the 2003 Medicare Part D prescription drug law already permits importing drugs under certain conditions, but HHS has never approved such a program.
Allowing drugs to be safely imported from Canada and other countries is one of the pillars of AARP's Stop Rx Greed campaign, which calls on federal and state officials to find ways to lower the price of lifesaving medicines for all Americans.
"Today's announcement is an important signal that the administration agrees that lower-priced drugs can be safely imported and that the FDA should use its full authority under law to help American consumers,” Nancy LeaMond, AARP executive vice president and chief advocacy and engagement officer, said in a statement. “Let's be clear: There is a crisis in drug prices, and the safe, legal importation of less expensive prescription drugs is one step that will help lower costs and add competitive pressure on drugmakers to lower the prices they set in the U.S."
More on politics-society
Specialty Drug Prices Soar to Nearly $79,000 a Year
AARP report finds costs average more than four times average annual Social Security benefitFight to Lower Prescription Drug Prices Continues at State Level
Big Pharma’s successful lawsuit won’t stop bipartisan movement